ClinicalTrials.gg
Enrolling by invitationNCT07877662QUERI VASTUpdated Oct 16, 2026

VA Quality Enhancement Research Initiative (QUERI) CARRIAGE VAST

An interventional study of Videoconference Antimicrobial Stewardship Team in Common Infections, Urinary Tract Infections and Respiratory Tract Infections, sponsored by VA Office of Research and Development. Enrolling by invitation at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Nov 2025, registered Sep 2026).
Updated Oct 16, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Sex
All
01

Study summary

Antimicrobial-resistant and healthcare-associated pathogens are a global health threat. The goals of antimicrobial stewardship are to minimize unnecessary and inappropriate antimicrobial use as a means to combat antimicrobial resistance. The interdisciplinary Videoconference Antimicrobial Stewardship Team (VAST) was initially developed and tested as a telehealth teleconferencing training and mentoring program in 2 rural pilot sites, then was extended to 9 rural sites, using telehealth to connect clinicians at a rural VAMC to a geographically distant infectious disease expert. Qualitative interviews showed that participants valued VAST and it improved patient care. This project will expand the VAST to other VAMCs and assess the VASTs' impact on antimicrobial prescribing. This work will directly increase access to antimicrobial stewardship consultation at rural VA facilities, which are often underserved by infectious disease expertise.

Read the detailed description

Background: Antimicrobial resistance (AMR) is a current pandemic. Access to ID physicians and pharmacists in VHA is limited and many VHA healthcare systems do not have an ID specialist. This gap in expertise is detrimental, as the presence of ID trained physicians and pharmacists in acute care is associated with improved antimicrobial utilization. Telehealth can facilitate antimicrobial stewardship in VA facilities underserved by ID expertise. The interdisciplinary Videoconference Antimicrobial Stewardship Team (VAST)consists of weekly meetings between an interdisciplinary team at a rural VAMC with an off-site ID trained physician and/or pharmacist who meet by videoconference. At each session, participants discuss patients receiving antibiotics or who may potentially receive antibiotics. Team members enter the VAST's recommendations into the electronic medical record (EMR) at the rural VAMC. The ID physicians capture their clinical effort by completing interfacility consults placed through the EMR. The aims of this hybrid effectiveness trial are to assess the implementation of VAST and antibiotic utilization outcomes.

Aim 1: Implement and evaluate the implementation of VAST, using an implementation playbook with external facilitation and tailoring. VAST will be implemented over 15 months, plus sustainability follow-up in 6 rural VAMCs using key implementation strategies of external facilitation provided by CARRIAGE, tailoring and adaptation of VAST, and use of an implementation playbook. Process maps (which informed the playbook) from the previous VAST expansion captured VAST experiences at each site and illuminated successful implementation processes, showing that tailoring and adapting the VAST program based on site-specific needs, individual clinical processes, and patient care needs was crucial to its success and sustainability. The playbook details the general process for setting up an e-consult VAST clinic and scheduling and conducting VAST sessions. Site-specific tailoring, adaptation, and facilitation of VAST will occur based on playbook information. CARRIAGE members will hold initial facilitation calls weekly with VASTs, with ad hoc support available as well. CARRIAGE will facilitate an initial kick off meeting via Teams for each VAST to encourage team building and expectations for the ensuing sessions.

Aim 2: Assess the impact of VAST on antimicrobial use and the care of Veterans with suspected and confirmed infections. Using a quasi-experimental design, the investigators will assess outcomes for new rural sites implementing VAST and for the current rural sites currently using VAST to assess sustainability. For each site, the investigators will calculate these statistics monthly for the 12 months prior to and 15 months following the first VAST session (allowing for a 3-month wash-in period), and up to 24 months to assess sustainability. The investigators will include a control group of rural sites not utilizing VAST (matched). Antibiotic use metrics including rates of total and broad-spectrum anti-biotic use, antibiotic starts, and length of antibiotic therapy will be evaluated. The primary outcome is days of antibiotic therapy per 1000 days of care (DOT/1000 DOC) to measure the overall rate of antibiotic use; key secondary outcomes include rate of broad-spectrum antibiotics, defined as agents with an Antibiotic Spectrum Index score of ≥ 8;72 rate of antibiotic starts, calculated as the number of new starts per 1000 DOC; and length of antibiotic therapy in days. Other outcomes may be evaluated including management of resistant infections including treatment selection. The investigators will use VA CDW/Millennium to obtain antimicrobial prescribing, diagnosis, comorbidity, microbiologic, laboratory, and demographic data.

02

Conditions studied

  • Common Infections
  • Urinary Tract Infections
  • Respiratory Tract Infections

Keywords

  • Antimicrobial stewardship
  • Telemedicine
  • Rural health
03

In context

Urinary Tract Infections

779 studies on the registry are indexed under Urinary Tract Infections; 132 are open to participants now.

This study's planned enrollment of 6 is below the median of 130 across 544 interventional studies indexed under Urinary Tract Infections.

Browse Urinary Tract Infections studies →

Lead sponsor

VA Office of Research and Development is the lead sponsor of 1,767 studies on the registry; 394 are open to participants now.

Of its 209 completed or terminated interventional studies of FDA-regulated products, 183 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-VA medical centers without local ID expertise that pair with an ID-expert from another VA medical center

Exclusion criteria

Exclusion Criteria:

-none

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Other
    VAST

    Sites that implement VAST

    Other: Videoconference Antimicrobial Stewardship Team

Interventions

  • OtherVideoconference Antimicrobial Stewardship Team

    Implementation of VAST in hybrid effectiveness trial. Sites that implement VAST will have outcomes measured before and after implementation of VAST. Implementation outcomes will be measured.

    Also known as: VAST

06

What researchers measure

Primary outcomes

  1. Days of Antibiotic Therapy (DOT) / 1000 Bed Days of Care (DOC)

    Days of antibiotic therapy per 1000 days of care (DOT/1000 DOC), measures the overall rate of antibiotic use and is a common metric that accounts for dose adjustments, including for people who receive dialysis. Administration of any dose of an antimicrobial on a given day represents a single DOT for that agent, regardless of the number of times the doses are administered or the dose strength.

    Time frame: 2.25 years

Secondary outcomes

  1. Antibiotic Starts

    The investigators will measure the rate of antibiotic starts (new prescriptions), calculated as the number of starts per 1000 DOC.

    Time frame: 2.25 years

  2. Rate of Broad-spectrum Antibiotics

    The investigators will specifically examine the rate of broad-spectrum antibiotics, defining broad-spectrum agents as those with an Antibiotic Spectrum Index (ASI) score of 8. This scale ranges from 1 to 13; the ASIs for penicillin, doxycycline, ciprofloxacin, and ertapenem are 2, 5, 8 and 9, respectively.

    Time frame: 2.25 years

Other outcomes

  1. Reach

    Reach will be measured by the number of Veterans served or discussed during VAST sessions.

    Time frame: 2 years

  2. Adoption

    Adoption will include the number of sessions completed by each VAST team, the number and description of attendee roles and practice settings, and the number of ID e-consults.

    Time frame: 2.25 years

  3. Implementation

    Implementation will include the number and types of recommendations for a sample of VAST meetings, the proportion of those recommendations accepted, and documentation of tailoring/adaptations.

    Time frame: 2 years

07

Study locations

1 site
  • Edward Hines Jr. VA Hospital, Hines, IL
    Hines, Illinois 60141-3030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07877662
Responsible party
Sponsor
First posted
Oct 16, 2026
Start date
Nov 24, 2025
Primary completion
Sep 30, 2030 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Oct 16, 2026

Study contacts

Charlesnika Tyon Evans, PhD MPH BS
principal investigator · Edward Hines Jr. VA Hospital, Hines, IL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion